An initial statement of beneficial ownership was filed on October 27, 2026, by Adam Schayowitz, newly appointed as a director of Faeth Therapeutics, Inc., reflecting his status as of the event date of October 23, 2026.

Key Highlights

  • Reporting person: Adam Schayowitz filed as a director of Faeth Therapeutics, Inc. (NASDAQ:FTH).
  • Event date: The date of the event requiring the statement was October 23, 2026.
  • Filing date: The statement was signed and filed on October 27, 2026, by Josiah Craver as attorney-in-fact.
  • No securities held: According to the filing, "No securities are beneficially owned," across both non-derivative and derivative security tables.
  • Filing scope: The statement was filed by one reporting person acting individually, not as part of a joint or group filing.

Director Schayowitz Reports No Beneficial Ownership at Faeth Therapeutics

Adam Schayowitz submitted an initial statement of beneficial ownership in connection with his appointment as a director of Faeth Therapeutics, Inc., the Austin, Texas-based therapeutics company listed on NASDAQ under the symbol FTH. The address of record listed in the filing is 701 Tillery Street #12 #1010, Austin, Texas 78702. The triggering event date, as stated in the filing, was October 23, 2026.

According to the filing, Schayowitz held no securities in either Table I, covering non-derivative securities, or Table II, covering derivative securities such as options, warrants, or convertible instruments. The filing states explicitly that "No securities are beneficially owned." The statement was signed on October 27, 2026, by Josiah Craver as attorney-in-fact, pursuant to a power of attorney listed as Exhibit 24 in the filing. The filing was submitted by one reporting person and was not a joint or group filing.

Faeth Therapeutics, Inc. is the issuer named in the filing. The company is identified with the ticker symbol FTH. As a director, Schayowitz is subject to the beneficial ownership reporting requirements of Section 16(a) of the Securities Exchange Act of 1934, which requires insiders to file an initial statement upon first becoming subject to those requirements. No shares or derivative positions were disclosed as held at the time of the filing.

What Was Disclosed

The filing disclosed that Adam Schayowitz became a director of Faeth Therapeutics, Inc. (NASDAQ:FTH) as of October 23, 2026, and reported no beneficial ownership of any class of securities, either direct or indirect, at the time of the filing.